Table 5.
Relationship between several markers and cancer caused death
| Cancer death (n) |
Total (n) |
Multivariate HRa (95% CI)a, b |
Multivariate HR (95% CI) c |
|
|---|---|---|---|---|
| Tumor grade | ||||
| High-middle | 83 | 193 | Reference | Reference |
| Low | 35 | 57 | 1.43 (1.10 ~ 1.86) | 1.41 (1.08 ~ 1.85) |
| Tumor stage | ||||
| LDa | 57 | 143 | Reference | Reference |
| EDa | 61 | 107 | 1.43 (1.10 ~ 1.85) | 1.42 (1.09 ~ 1.84) |
| EGFRa | ||||
| Negative | 90 | 202 | Reference | Reference |
| Positive | 28 | 48 | 1.31 (0.99 ~ 1.74) | 1.30 (0.98 ~ 1.73) |
| KRASa | ||||
| Negative | 108 | 234 | Reference | Reference |
| Positive | 10 | 16 | 1.35 (0.90 ~ 2.03) | 1.33 (0.88 ~ 2.01) |
| Serum PD-L1a | ||||
| <7.1 ng/ml | 48 | 124 | Reference | Reference |
| ≥ 7.1 ng/ml | 70 | 126 | 1.44 (1.09 ~ 1.88) | 1.43 (1.08 ~ 1.87) |
| Tissue PD-L1 | ||||
| Negative | 19 | 50 | Reference | Reference |
| Positive | 33 | 48 | 1.85 (1.24 ~ 2.75) | 1.86 (1.24 ~ 2.76) |
aLD Limited disease, ED Extensive disease, EGFR Epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene, PD-L1 Programmed death ligand 1, HR Hazard ratio, CI Confidence interval
bThe model was adjusted by age and gender
cThe model was adjusted by age, gender, smoking history, performance status, tumor grade, tumor stage, tissue expressions of epidermal growth factor receptor and kirsten rat sarcoma viral oncogene